These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37623842)

  • 1. Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions: Research Methods and Applications.
    Sun L; Mi K; Hou Y; Hui T; Zhang L; Tao Y; Liu Z; Huang L
    Metabolites; 2023 Jul; 13(8):. PubMed ID: 37623842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
    Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
    Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
    Gomez-Mantilla JD; Huang F; Peters SA
    Clin Pharmacokinet; 2023 Mar; 62(3):457-480. PubMed ID: 36752991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined
    Ji B; Xue Y; Xu Y; Liu S; Gough AH; Xie XQ; Wang J
    ACS Chem Neurosci; 2021 May; 12(10):1777-1790. PubMed ID: 33950681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development.
    Lu C; Di L
    Biopharm Drug Dispos; 2020 Feb; 41(1-2):3-31. PubMed ID: 31778578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
    Leow JWH; Ang XJ; Chan ECY
    Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
    Min JS; Bae SK
    Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of Prediction Methods for Drug-Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates].
    Yoshikado T
    Yakugaku Zasshi; 2023; 143(1):11-19. PubMed ID: 36596534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual Clinical Trial Toward Polytherapy Safety Assessment: Combination of Physiologically Based Pharmacokinetic/Pharmacodynamic-Based Modeling and Simulation Approach With Drug-Drug Interactions Involving Terfenadine as an Example.
    Wiśniowska B; Polak S
    J Pharm Sci; 2016 Nov; 105(11):3415-3424. PubMed ID: 27640752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.
    Fuhr LM; Marok FZ; Mees M; Mahfoud F; Selzer D; Lehr T
    Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic/Pharmacodynamic and Study Design Considerations.
    Sun H; Sivasubramanian R; Vaidya S; Barve A; Jarugula V
    J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S49-S62. PubMed ID: 33274510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic-pharmacodynamic model based on multi-organ-on-a-chip for drug-drug interaction studies.
    Shinha K; Nihei W; Ono T; Nakazato R; Kimura H
    Biomicrofluidics; 2020 Jul; 14(4):044108. PubMed ID: 34992705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib.
    Liu H; Yu Y; Liu L; Wang C; Guo N; Wang X; Xiang X; Han B
    Front Pharmacol; 2022; 13():970539. PubMed ID: 36091758
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
    Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
    Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes.
    Wang NN; Wang XG; Xiong GL; Yang ZY; Lu AP; Chen X; Liu S; Hou TJ; Cao DS
    J Cheminform; 2022 Apr; 14(1):23. PubMed ID: 35428354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.